Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Hormone or other secreted growth regulatory factor,...
Reexamination Certificate
2004-08-12
2009-02-03
Bunner, Bridget E (Department: 1647)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Hormone or other secreted growth regulatory factor,...
C424S184100, C530S350000, C530S399000
Reexamination Certificate
active
07485310
ABSTRACT:
The present invention disclosed the expression of CXCL6 by cells which are able to form stable cartilage. The invention describes the use of these cells and of CXCL6 to promote cartilage (and underlying bone) formation e.g. in the repair of cartilage or osteochondral defects. The invention further describes the use of chemokines in the modulation of progenitor cell differentiation.
REFERENCES:
patent: 5786217 (1998-07-01), Tubo et al.
patent: 5840524 (1998-11-01), Van Damme et al.
patent: 6410268 (2002-06-01), Ni et al.
patent: 6413511 (2002-07-01), Glorioso et al.
patent: 2002/0123483 (2002-09-01), Saxena et al.
patent: 2005/0019865 (2005-01-01), Kihm et al.
patent: 2006/0153817 (2006-07-01), Kihm et al.
patent: 2006/0154366 (2006-07-01), Brown et al.
patent: 2006/0154367 (2006-07-01), Kihm et al.
patent: 1 312 614 (2003-05-01), None
Haringman et al. Chemokines in joint disease: the key to inflammation? Ann Rheumatic Diseases 63(10): 1186-1194, 2004.
Wuyts et al. Characterization of synthetic human granulocyte chemotactic protein 2: usage of chemokine receptors CXCR1 and CXCR2 and in vivo inflammatory properties. Biochemistry 36(9): 2716-2723, 1997.
Lindahl et al. “Cartilage repair with chondrocytes: Clinical and cellular aspects” in Tissue Engineering of Cartilage and Bone. Novartis Foundation Symposium 249. 2003. UK: John Wiley and Sons, Ltd., pp. 175-189.
Imhof et al. Subchondral bone and cartilage disease. Invest Radiol 35(10): 581-588, 2000.
Meyer and Wiesmann. Bone and Cartilage. 2006. Germany: Springer, pp. 7-46.
International Preliminary Report on Patentability (PCT/BE2004/000117) (mailed Dec. 5, 2005).
International Search Report (PCT/BE2004/000117) (mailed Feb. 2, 2005).
Response to the Written Opinion (PCT/BE2004/000117) (mailed Jun. 1, 2005).
Written Opinion of the International Searching Authority (PCT/BE2004/000117) (mailed Feb. 2, 2005).
Wuyts et al., “The CXC Chemokine GCP-2/CXCL6 is Predominantly Induced in Mesenchymal Cells by Interleukin-1β and is Down-Regulated by Interferon-γ: Comparison with Interleukin-8/CXCL8,”Lab. Invest.83:23-34 (2003).
Translation of Office Action mailed Jul. 9, 2008 in connection with Russian Patent Application No. 2006107536/(008178).
De Bari Cosimo
Dell'Accio Francesco
Luyten Frank
Bunner Bridget E
Clark & Elbing LLP
Tigenix N.V.
LandOfFree
Use of CXCL6 chemokine in the prevention or repair of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of CXCL6 chemokine in the prevention or repair of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of CXCL6 chemokine in the prevention or repair of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4064077